- Home
- PHM vs BIIB Comparison
PHM vs BIIB Comparison
Compare PHM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHM
- BIIB
- Stock Information
- Founded
- PHM 1950
- BIIB 1978
- Country
- PHM United States
- BIIB United States
- Employees
- PHM N/A
- BIIB N/A
- Industry
- PHM Homebuilding
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- PHM Consumer Discretionary
- BIIB Health Care
- Exchange
- PHM Nasdaq
- BIIB Nasdaq
- Market Cap
- PHM 20.5B
- BIIB 19.9B
- IPO Year
- PHM N/A
- BIIB 1991
- Fundamental
- Price
- PHM $94.95
- BIIB $118.61
- Analyst Decision
- PHM Buy
- BIIB Buy
- Analyst Count
- PHM 16
- BIIB 28
- Target Price
- PHM $135.67
- BIIB $220.29
- AVG Volume (30 Days)
- PHM 2.5M
- BIIB 1.9M
- Earning Date
- PHM 04-22-2025
- BIIB 05-01-2025
- Dividend Yield
- PHM 0.93%
- BIIB N/A
- EPS Growth
- PHM 25.30
- BIIB 40.28
- EPS
- PHM 14.69
- BIIB 11.18
- Revenue
- PHM $17,946,950,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- PHM $1.03
- BIIB N/A
- Revenue Next Year
- PHM $5.59
- BIIB N/A
- P/E Ratio
- PHM $6.46
- BIIB $10.61
- Revenue Growth
- PHM 11.74
- BIIB N/A
- 52 Week Low
- PHM $88.07
- BIIB $110.04
- 52 Week High
- PHM $149.47
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- PHM 41.97
- BIIB 38.12
- Support Level
- PHM $91.99
- BIIB $110.04
- Resistance Level
- PHM $96.67
- BIIB $119.99
- Average True Range (ATR)
- PHM 4.94
- BIIB 5.59
- MACD
- PHM -0.37
- BIIB -0.68
- Stochastic Oscillator
- PHM 42.16
- BIIB 30.65
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.